Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1347178/000134717820000003/vnda1231201910k.htm
December 2022
December 2022
December 2022
November 2022
August 2022
June 2022
May 2022
March 2022
February 2022
February 2022
Exhibit 99.1
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
| Full year 2019 total revenues grew to $227.2 million, an 18% increase compared to 2018 |
| Full year 2020 total revenues expected to be between $240 million and $260 million |
| Results from the EPIONE study of Tradipitant in the treatment of Pruritus in Atopic Dermatitis reported today |
WASHINGTON February 25, 2020 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq:
VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2019.We had another year of outstanding commercial growth, said Mihael H. Polymeropoulos, M.D., Vandas President and CEO. I have never been more excited about the opportunities ahead with our relentless focus on developing innovative therapies for patients in need.
Key Financial Highlights
| Total revenues were $60.9 million in the fourth quarter of 2019, a 15% increase compared to $53.0 million in the fourth quarter of 2018. Total revenues were $227.2 million for the full year 2019, an 18% increase compared $193.1 million for the full year 2018. |
| HETLIOZ® net product sales were $38.6 million in the fourth quarter of 2019, a 19% increase compared to $32.4 million in the fourth quarter of 2018. HETLIOZ® net product sales were $143.0 million for the full year 2019, a 23% increase compared to $115.8 million for the full year 2018. |
| Fanapt® net product sales were $22.3 million in the fourth quarter of 2019, an 8% increase compared to $20.6 million in the fourth quarter of 2018. Fanapt® net product sales were $84.2 million for the full year 2019, a 9% increase compared to $77.3 million for the full year 2018. |
| Cash, cash equivalents and marketable securities (Cash) were $312.1 million as of December 31, 2019, representing an increase to Cash of $54.8 million compared to December 31, 2018. |
Key Product and Pipeline Highlights
Tradipitant
| Results from the EPIONE study of tradipitant in the treatment of pruritus in atopic dermatitis were reported today. Vanda will reassess EPIONE 2 and determine next steps. |
| Enrollment in the Phase III study of tradipitant in gastroparesis (VP-VLY-686-3301) is ongoing. |
| Vanda expects to complete the Phase III program of tradipitant in motion sickness and file a New Drug Application with the U.S. Food and Drug Administration (FDA) in 2020. |
| Vanda continues to engage with the FDA over the requirement of a 9-month dog toxicity study. |
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1347178/000134717820000003/vnda1231201910k.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Vanda Pharmaceuticals Inc..
Vanda Pharmaceuticals Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:
Rating
Learn More![]()
Factors we consider important which could trigger an impairment review include significant underperformance relative to expected historical or projected future operating results, a significant adverse change in legal or regulatory factors that could affect the value or patent life including our ability to defend and enforce patent claims and other intellectual property rights and significant negative industry or economic trends.
If we raise additional capital by issuing equity securities, the terms and prices for these financings may be much more favorable to the new investors than the terms obtained by our existing stockholders.
(1) We record direct costs, including personnel costs and related benefits, on a project-by-project basis.
Our cash and cash equivalents are deposits in operating accounts and highly liquid investments with an original maturity of 90 days or less at date of purchase and consist of investments in money market funds with commercial banks and financial institutions, and commercial paper of high-quality corporate issuers.
In addition, we expect to incur licensing costs in the future that could be substantial, as we continue our efforts to expand our product pipeline.
Cash flows used in investing...Read more
Cash flows provided by financing...Read more
No impairments have been recognized...Read more
Our future capital requirements and...Read more
We expect to incur substantial...Read more
We amortize our intangible assets...Read more
Our intangible assets consist of...Read more
Selling, general and administrative expenses...Read more
Cost of goods sold increased...Read more
The following table summarizes the...Read more
Research and development expenses increased...Read more
Public Law No. 115-123, also...Read more
In accordance with ASC Subtopic...Read more
Third party royalty costs on...Read more
Allowances for rebates, chargebacks and...Read more
We record indirect costs that...Read more
The provision for discounts, returns...Read more
The actual costs to advance...Read more
The issuance of debt could...Read more
We accrue service fees at...Read more
For all leases entered into...Read more
For leases with a term...Read more
The analysis is highly dependent...Read more
(4) This table does not...Read more
When we determine that the...Read more
The Company evaluates outstanding receivables...Read more
This table does not include...Read more
Fanapt product sales, net increased...Read more
Intangible Assets....Read more
Uncertainties related to variable consideration...Read more
Total revenues increased by $34.1...Read more
Medicare Part D Coverage Gap:...Read more
Revenues were as follows: HETLIOZ...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Material Contracts, Statements, Certifications & more
Vanda Pharmaceuticals Inc. provided additional information to their SEC Filing as exhibits
Ticker: VNDA
CIK: 1347178
Form Type: 10-K Annual Report
Accession Number: 0001347178-20-000003
Submitted to the SEC: Wed Feb 26 2020 7:02:16 AM EST
Accepted by the SEC: Wed Feb 26 2020
Period: Tuesday, December 31, 2019
Industry: Pharmaceutical Preparations